PMID- 35491151
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220503
IS  - 1347-5231 (Electronic)
IS  - 0031-6903 (Linking)
VI  - 142
IP  - 5
DP  - 2022
TI  - [Role of Fatty Acid Elongase Elovl6 in the Regulation of Fatty Acid Quality and 
      Lifestyle-related Diseases].
PG  - 473-476
LID - 10.1248/yakushi.21-00176-4 [doi]
AB  - The increasing prevalence of obesity worldwide has become an alarming public 
      health concern because of dramatic increases in the incidence of 
      obesity-associated diseases, including type 2 diabetes mellitus (T2DM). 
      Peripheral insulin resistance and impaired insulin secretion remain the core 
      defects in T2DM. Despite significant advances in unraveling the mechanisms 
      underlying these defects, many of the metabolic pathways and regulators involved 
      in insulin resistance and beta-cell dysfunction are not completely understood. This 
      review proposes that manipulating the fatty acid (FA) composition by blocking 
      ELOVL fatty acid elongase 6 (Elovl6) could protect against insulin resistance, 
      impaired insulin secretion, and obesity-related disorders. Elovl6 is a microsomal 
      enzyme involved in the elongation of C16 saturated and monounsaturated FAs to 
      form C18 FAs. We have reported that mice with Elovl6 deletion are protected 
      against obesity-induced insulin resistance or beta-cell failure because the cellular 
      FA composition is changed, even with concurrent obesity. Therefore, Elovl6 
      appears to be a crucial metabolic checkpoint, and limiting the expression or 
      activity of Elovl6 could be a new therapeutic approach in the treatment of T2DM.
FAU - Matsuzaka, Takashi
AU  - Matsuzaka T
AD  - Department of Endocrinology and Metabolism, Transborder Medical Research Center, 
      Faculty of Medicine, University of Tsukuba.
FAU - Shimano, Hitoshi
AU  - Shimano H
AD  - Department of Endocrinology and Metabolism, Transborder Medical Research Center, 
      Faculty of Medicine, University of Tsukuba.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Yakugaku Zasshi
JT  - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
JID - 0413613
RN  - 0 (Fatty Acids)
RN  - EC 2.3.1.- (Acetyltransferases)
RN  - EC 2.3.1.- (Fatty Acid Elongases)
SB  - IM
MH  - Acetyltransferases/genetics/metabolism
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Fatty Acid Elongases
MH  - Fatty Acids/metabolism
MH  - *Insulin Resistance
MH  - Life Style
MH  - Mice
MH  - Mice, Knockout
MH  - Obesity/complications
OTO - NOTNLM
OT  - ELOVL fatty acid elongase 6 (Elovl6)
OT  - diabetes
OT  - fatty acid
OT  - lipotoxicity
OT  - obesity
EDAT- 2022/05/02 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/05/01 21:53
PHST- 2022/05/01 21:53 [entrez]
PHST- 2022/05/02 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
AID - 10.1248/yakushi.21-00176-4 [doi]
PST - ppublish
SO  - Yakugaku Zasshi. 2022;142(5):473-476. doi: 10.1248/yakushi.21-00176-4.